通过不同患者组的-葡萄糖共运输体2抑制剂改善心力衰竭结果
1BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Diabetes, obesity & metabolism
|June 19, 2023
概括
-葡萄糖共运输体2抑制剂 (SGLT-2is) 显著减少心力衰竭住院和心血管事件. 这些好处适用于患有2型糖尿病,心力衰竭和慢性病的患者,无论糖尿病状况如何.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
背景情况:
- -葡萄糖共运输体2抑制剂 (SGLT-2is) 最初是用于2型糖尿病的治疗.
- 心血管 (CV) 结局试验揭示了超出血糖控制的心力衰竭 (HF) 的意想不到的好处.
研究的目的:
- 评估SGLT-2抑制剂在减少HF住院和心血管死亡方面的疗效.
- 评估SGLT-2抑制剂对不同患者群体的影响,包括患有或没有2型糖尿病和慢性脏病的患者.
主要方法:
- 来自大型随机CV结局试验和随后的SGLT-2抑制剂试验的数据分析.
- 包括2型糖尿病患者,不同排泄分数的高血压,以及带有白尿的慢性病患者.
主要成果:
- 在2型糖尿病患者中,SGLT-2降低了HF住院率30%和CV死亡或HF住院率21%.
- 在HF患者 (减少,轻微减少或保留喷射分数) 中,HF住院病例减少了28%,心血管死亡或HF住院病例减少了23%.
- 在患有白病的慢性病患者中,SGLT-2导致HF住院率降低44%,CV死亡或HF住院率降低25%.
结论:
- SGLT-2 抑制剂在广泛的患者群体中有效改善高血压结局.
- 在高血压中,SGLT-2抑制剂的益处不论是否存在2型糖尿病都被观察到.
- SGLT-2 抑制剂正在成为HF治疗的核心疗法,并支持在2型糖尿病,CKD和HF患者中使用.
相关概念视频
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:22Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
469
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
469
01:26Heart Failure Drugs: Inotropic Agents
641
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
641
01:30Heart Failure IV: Classification and Diagnostic Evaluation
21
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
21
01:22Heart Failure Drugs: Diuretics
426
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
426